[Evidence-based medicine and drug selection of osleoporosis prevention after menopause].
Xu
Ling
L
D002681:China / Q000453:epidemiology; D004353:Drug Evaluation, Preclinical; D004965:Estrogen Antagonists / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000453:epidemiology; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D004965:Estrogen Antagonists; D004967:Estrogens; D020849:Raloxifene Hydrochloride